Since immune checkpoint blockade with PD-L1 antibodies can generate durable responses in patients with advanced NSCLC [12], the immune escape represents one of the major hurdles to be overcome to improve clinical outcomes in patients treated with immunotherapy [13]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.